QMS Medical Allied Services FY26: Revenue Climbs to ₹173 Cr, Profit Slips to ₹10 Cr — and the Ticker Just Changed Boards

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

QMS Medical Allied Services closed FY26 with a split-screen result. Revenue rose to ₹172.9 crore from ₹155.8 crore, an 11% climb. Net profit went the other way, sliding to ₹10.1 crore from ₹12.1 crore — a 16% fall. So the top line grew and the bottom line shrank in the same year, which is the kind of tension a reference entry exists to record.

Two structural facts frame the year. First, the company migrated from NSE Emerge to the NSE Mainboard on 18 June 2026, its 1.93 crore shares moving to the bigger stage after four years on the SME platform. Second, the fourth quarter carried the profit damage: Q4FY26 net profit landed at ₹1.72 crore against ₹3.34 crore a year earlier, a 48.5% drop, on near-flat quarterly sales.

The attention signal is a business that grew revenue for the year while spending its way through a soft quarter. The worry signal sits in working capital — receivables and the cash conversion cycle both stretched. A company can invest ahead of revenue and call it strategy; the accounts simply record the timing gap. The rest of this entry lays out the numbers behind that gap.

2. Introduction

QMS was incorporated in its current corporate form in 2017, though the operating lineage runs back to 1994 as a pharma-marketing and medical-device distribution business. It distributes third-party brands — 3M, Heine, Rossmax among them — alongside its own Q-Devices label launched in FY21, covering glucometers, oximeters, BP monitors and similar hardware. Over 900 SKUs move to 130-plus institutional clients, including a long list of pharmaceutical companies.

The more recent chapter is services. The company built out patient support programs (PSPs), B2B screening camps and medical-education content, and folded in Saarathi Healthcare, whose stake management raised to 76% during the year. By FY26 the split was 69% products, 31% services, with management stating the intent to tilt the mix toward the higher-margin service side over time.

Two events dominated the year’s filings: the mainboard migration in June 2026, and a rights issue that brought in roughly ₹10.4 crore, lifting the share count from 1.785 crore to 1.934 crore. The board also recommended a dividend of ₹0.50 per share for FY26 — the first on record here. Everything else this entry discusses hangs off those moves and the numbers around them.

3. Business Model: WTF Do They Even Do?

Strip away the healthcare-ecosystem language and QMS runs two shops under one roof.

Shop one is distribution. QMS buys or sources medical devices — the third-party global brands plus its own Q-Devices line — and sells them to pharma companies, hospitals, clinics, and through its QMSMEDS e-commerce portal and the government eGrameen channel. It’s a margin-taking middleman with a house brand bolted on for better economics. Management pegs product-side EBITDA margins in the roughly 10–12% band. Honest work, thin spreads, and 900 SKUs to babysit.

Shop two is where the interesting money hides. The services arm sells three things: pharma-sponsored screening camps (32,380 of them conducted in FY26), patient support programs run under fixed-cost-plus contracts, and small high-margin medical-education content. The camps run on a pay-per-camp model where the pharma company foots the bill — not the patient, not the doctor. Management stated services-side EBITDA margins sit around 25%, more than double the product side. The strategic pitch writes itself: sell more of shop two, less of shop one.

The catch is that shop two costs money up front. PSP contracts get signed months before billing starts, and the staff to run them get hired first. So the services pivot that improves the margin mix on paper also front-loads the expense line — which is precisely the story FY26’s profit told.

A model where your best-margin business bills you before it pays you is a working-capital business wearing a growth-stock costume. Does the mix shift toward 25% services margins fix a 6% net margin, or just move the strain from the P&L to the balance sheet?

4. Financials Overview

Figures are consolidated, in ₹ crore.

Revenue compounded steadily across the three years. Operating profit rose sharply from FY24 to FY25, then flattened in FY26 — ₹25.4 crore to ₹25.9 crore, essentially unchanged while revenue added ₹17 crore. That flat operating line, sitting under a rising top line, is the whole FY26 story in one row: the incremental revenue arrived without incremental operating profit.

PAT then fell below the operating line’s implication because interest cost climbed to ₹6.6 crore from ₹4.6 crore as borrowings grew. Management attributed the softer profit to front-loaded hiring plus technology and data-compliance spending ahead of contracted service ramps, with billing on those contracts starting in April.

Concall note (Jun 2026): management reiterated FY27 revenue guidance of ₹216 crore and an EBITDA-margin expectation in the 18–19% range, citing locked-in service contracts and caution on the product supply chain. That figure is management’s forward statement, recorded here as theirs, not adopted as a forecast.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays about 20.7x earnings here versus a peer median of 36.8x across the listed medical-device set. Current ROE of 10.4% sits below the company’s own three-year average of 12.0%. ROCE of 13.2% sits below its FY25 level of 17% and just under the peer median of 14.9%.

What the market appears to be pricing is a services-mix transition that management has flagged but the FY26 accounts haven’t yet delivered — margins guided higher for FY27, a doubled services line, and a ₹216 crore revenue target, all against a year where profit actually fell. The multiple sitting below the peer set is consistent with a market weighing an 11% revenue year against a 16% profit decline. The observation the numbers support: the market is currently paying a lower earnings multiple here than for the peer group, while the company’s returns ratios run below their own recent history.

6. What’s Cooking

Four filed events, no invention required.

The mainboard migration completed on 18 June 2026, moving 1.93 crore shares off NSE Emerge. Management framed it as a liquidity and visibility step and, in the same release, set a stated ambition of ₹500 crore revenue by FY29 — recorded here as management’s target.

The rights issue brought in roughly ₹10.4 crore during the year, visible in the financing cash flow. The Saarathi Healthcare stake was raised to 76%, deepening the services arm. And the board recommended a maiden dividend of ₹0.50 per share for FY26. A first dividend in the same year profit declined is a governance choice the record simply notes.

7. Balance Sheet

Assets equal liabilities in every column.

• Borrowings roughly doubled over two years, from ₹34.5 crore to ₹67.5 crore, funding the services build-out and the balance-sheet expansion.
• Receivables jumped to ₹67.3 crore from ₹43.2 crore — a 56% rise against 11% revenue growth. The money is being earned on paper faster than it’s being collected.
• Cash sat at ₹1.2 crore against ₹67.5 crore of borrowings, so this is a net-debt balance sheet, not a net-cash one.

Net worth grew mostly through retained earnings plus the rights issue. A balance sheet can expand on borrowed money and issued equity at the same time; this one did both.

8. Cash Flow: Sab Number Game Hai

The story traces cleanly. FY25 was the heavy year — ₹45.5 crore going out on investing (the Saarathi consolidation and asset build) funded by ₹25.9 crore of financing inflows. FY26 calmed down: operating cash of ₹19.4 crore comfortably exceeded reported net profit of ₹10.1 crore, and investing outflow halved. Operating cash running ahead of book profit is the reassuring line in an otherwise strained year.

9. Ratios: Sexy or Stressy?

ROE of 10.4% means the equity is earning a middling return — working, but not straining itself. ROCE of 13.2% slipped from 17% a year earlier as the capital base grew faster than operating returns. The PAT margin of 5.9% shows how thin the net take is once distribution economics and rising interest are accounted for. D/E of 0.65 is moderate leverage, up as borrowings climbed. Debtor days stretched to 142 from 101, and the cash conversion cycle ran to roughly 250 days — a business that ties up cash for the better part of a year between spending and collecting.

10. P&L Breakdown: Show Me the Money

Other income is small relative to operating profit across all three years, so the profit here is real business, not one-off gains propping up the headline. The trajectory is the point: operating profit essentially flat FY25 to FY26 while revenue rose, and PAT falling as interest cost climbed.

EPS guard: EPS fell to ₹5.24 from ₹6.26, a steeper drop than PAT’s. Part of that is the rights issue lifting the share count from 1.785 crore to 1.934 crore — more shares dividing a smaller profit. So the per-share decline overstates the operating story slightly; the profit genuinely fell, and dilution deepened the per-share cut.

11. Peer Comparison

QMS is the smallest quarterly earner in the set and carries the lowest multiple in the group. The listed peers command P/Es ranging from the low 20s to near 100x; QMS sits at the bottom of that band at 20.7x, on the smallest profit base. The peer median multiple of 36.8x is roughly 1.8x what the market currently pays here.

12. Miscellaneous: Shareholding & Promoters

Promoter holding fell to 68.11% from 73.67%, a 5.56-point decline over the recent period. Founder Mahesh Makhija, Chairman & Managing Director, holds the bulk at 66.45%; he founded the operating business in 1994 and leads strategy and M&A. Institutional presence is thin — DIIs at 1.59%, FIIs at zero. Pledged shares stand at zero. The promoter roast writes itself only mildly: the family that trimmed its own stake by five-plus points is the same one recommending the company’s first dividend in the year profit fell.

13. Corporate Governance: Angels or Devils?

The auditor, H.H. Dedhia & Associates, issued an unmodified opinion on the FY26 consolidated and standalone results — a clean report. The internal auditor, Khushbu Parekh & Co., was reappointed for FY27. No share pledges, no investor complaints pending, and the board carries independent directors including a chartered accountant.

The features worth recording as facts, not verdicts: the board is family-anchored, with the CMD, a medical-training director and the e-commerce head all from the Makhija family, and the P&L carries related-party activity. Governance here reads as a clean audit trail sitting on a closely held, family-run structure — both things true at once.

14. Industry Roast & Macro Context

The Indian medical-device distribution game is a margin-compression machine, and QMS knows it — which is exactly why it’s sprinting toward services. Pure distribution means competing on price against anyone with a CDSCO license and a warehouse, while online-funded pharma platforms squeeze the commodity end. Management’s answer is to move up the value chain into patient adherence programs, where regulatory limits on direct pharma promotion are pushing spend toward structured PSPs and camps.

The sector tailwind is real: chronic-disease burden, an organizing shift from unorganized players, and pharma budgets migrating from product promotion to patient engagement. The sector’s problem is equally real — it’s a services promise layered on a distribution reality, and the two run on very different working-capital clocks. Everyone in the space is telling the same margin-migration story; the accounts decide who’s actually walking it.

15. EduInvesting Verdict

FY26 is a year the company spent building a services engine while the product engine idled — revenue up, profit down, working capital stretched, and a fresh board listing to grow into. Management’s ₹216 crore FY27 guidance and 18–19% margin target frame the payback it expects; the FY26 accounts frame the cost it paid first.

A revenue line that grew, a profit line that didn’t, and a balance sheet now carrying the weight of a bet on next year.